Nothing Special   »   [go: up one dir, main page]

IS4754A - Genaferjur og aðferðir fyrir genaflutning inn í frumur - Google Patents

Genaferjur og aðferðir fyrir genaflutning inn í frumur

Info

Publication number
IS4754A
IS4754A IS4754A IS4754A IS4754A IS 4754 A IS4754 A IS 4754A IS 4754 A IS4754 A IS 4754A IS 4754 A IS4754 A IS 4754A IS 4754 A IS4754 A IS 4754A
Authority
IS
Iceland
Prior art keywords
coat protein
cells
vector
methods
chimeric
Prior art date
Application number
IS4754A
Other languages
English (en)
Inventor
J. Wickham Thomas
Kovesdi Imre
E. Brough Douglas
Original Assignee
Genvec, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/563,368 external-priority patent/US5965541A/en
Priority claimed from US08/700,846 external-priority patent/US5962311A/en
Priority claimed from US08/701,124 external-priority patent/US5846782A/en
Application filed by Genvec, Inc. filed Critical Genvec, Inc.
Publication of IS4754A publication Critical patent/IS4754A/is

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10345—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/40—Vectors comprising a peptide as targeting moiety, e.g. a synthetic peptide, from undefined source
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/40—Vectors comprising a peptide as targeting moiety, e.g. a synthetic peptide, from undefined source
    • C12N2810/405—Vectors comprising RGD peptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IS4754A 1995-11-28 1998-05-25 Genaferjur og aðferðir fyrir genaflutning inn í frumur IS4754A (is)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US08/563,368 US5965541A (en) 1995-11-28 1995-11-28 Vectors and methods for gene transfer to cells
US08/700,846 US5962311A (en) 1994-09-08 1996-08-21 Short-shafted adenoviral fiber and its use
US08/701,124 US5846782A (en) 1995-11-28 1996-08-21 Targeting adenovirus with use of constrained peptide motifs
PCT/US1996/019150 WO1997020051A2 (en) 1995-11-28 1996-11-27 Vectors and methods for gene transfer to cells

Publications (1)

Publication Number Publication Date
IS4754A true IS4754A (is) 1998-05-25

Family

ID=27415918

Family Applications (1)

Application Number Title Priority Date Filing Date
IS4754A IS4754A (is) 1995-11-28 1998-05-25 Genaferjur og aðferðir fyrir genaflutning inn í frumur

Country Status (17)

Country Link
EP (3) EP1518933A1 (is)
JP (1) JP3420586B2 (is)
AT (1) ATE382694T1 (is)
AU (1) AU724189B2 (is)
BG (1) BG102554A (is)
BR (1) BR9612685A (is)
CA (1) CA2236912C (is)
CZ (1) CZ162398A3 (is)
EA (1) EA199800475A1 (is)
EE (1) EE9800160A (is)
IL (1) IL124654A0 (is)
IS (1) IS4754A (is)
NO (1) NO982417L (is)
NZ (1) NZ323834A (is)
PL (1) PL327038A1 (is)
SK (1) SK72298A3 (is)
WO (1) WO1997020051A2 (is)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6465253B1 (en) 1994-09-08 2002-10-15 Genvec, Inc. Vectors and methods for gene transfer to cells
US5962311A (en) * 1994-09-08 1999-10-05 Genvec, Inc. Short-shafted adenoviral fiber and its use
US5846782A (en) 1995-11-28 1998-12-08 Genvec, Inc. Targeting adenovirus with use of constrained peptide motifs
US5770442A (en) * 1995-02-21 1998-06-23 Cornell Research Foundation, Inc. Chimeric adenoviral fiber protein and methods of using same
FR2761689B1 (fr) * 1997-04-02 1999-06-25 Transgene Sa Fibre adenovirale modifiee et adenovirus cibles
DK1025211T3 (da) 1997-10-31 2005-04-04 Univ Oklahoma Hyaluronansyntasegen og anvendelser deraf
EP1044274A2 (en) * 1998-01-16 2000-10-18 Genzyme Corporation Adenoviral vectors with modified capsid proteins
US20030017138A1 (en) * 1998-07-08 2003-01-23 Menzo Havenga Chimeric adenoviruses
WO2000012738A1 (en) * 1998-08-27 2000-03-09 Aventis Pharma S.A. Targeted adenovirus vectors for delivery of heterologous genes
IL133032A (en) * 1998-11-20 2007-06-03 Introgene Bv Adenoviral gene delivery vectors provided with a tissue tropism for smooth muscle cells and /or endothelial cells
EP1020529B1 (en) * 1998-11-20 2005-06-01 Crucell Holland B.V. Gene delivery vectors provided with a tissue tropism for smooth muscle cells, and/or endothelial cells
DE60039683D1 (de) * 1999-03-04 2008-09-11 Crucell Holland Bv Verwendung eines adenovirusvektors zur transduktion von synovialen zellen
WO2001002431A1 (en) * 1999-07-06 2001-01-11 Got-A-Gene Ab Recombinant adenovirus
US6955808B2 (en) * 1999-09-24 2005-10-18 Uab Research Foundation Capsid-modified recombinant adenovirus and methods of use
WO2001081607A2 (en) * 2000-04-26 2001-11-01 Crucell Holland B.V. Adenovirus vectors with knobless fibers, and their uses
US6849446B2 (en) * 2000-05-31 2005-02-01 University Of Saskatchewan Modified bovine adenovirus having altered tropism
US6579522B1 (en) * 2000-06-27 2003-06-17 Genvec, Inc. Replication deficient adenoviral TNF vector
GB0017720D0 (en) * 2000-07-19 2000-09-06 Got A Gene Ab Modified virus
US6573092B1 (en) 2000-10-10 2003-06-03 Genvec, Inc. Method of preparing a eukaryotic viral vector
US20030086903A1 (en) 2001-11-02 2003-05-08 Genvec, Inc. Therapeutic regimen for treating cancer
US20040166091A1 (en) 2003-02-24 2004-08-26 Genvec, Inc. Materials and methods for treating disorders of the ear
US7611868B2 (en) 2003-05-14 2009-11-03 Instituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Recombinant modified adenovirus fiber protein
EP1687032B1 (en) 2003-11-14 2010-02-24 Genvec, Inc. Pharmaceutical composition for treating unresectable, locally advanced pancreatic cancer (lapc).
JP2007228802A (ja) * 2004-03-31 2007-09-13 Dnavec Research Inc 標的細胞への遺伝子の導入方法
EP1737885A2 (en) 2004-04-12 2007-01-03 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Method of using adenoviral vectors to induce an immune response
US7964196B2 (en) 2004-05-25 2011-06-21 Chimeros, Inc. Self-assembling nanoparticle drug delivery system
CA2620495A1 (en) 2005-08-31 2007-03-08 Genvec, Inc. Adenoviral vector-based malaria vaccines
EP1951297A2 (en) 2005-11-10 2008-08-06 GenVec, Inc. Adenoviral vector-based foot-and-mouth disease vaccine
DE602007005366D1 (de) 2006-04-07 2010-04-29 Chimeros Inc Zusammensetzungen und verfahren zur behandlung von b-zellen-malignomen
WO2010120874A2 (en) 2009-04-14 2010-10-21 Chimeros, Inc. Chimeric therapeutics, compositions, and methods for using same
US20120219583A1 (en) 2009-10-16 2012-08-30 Los Alamos National Security, Llc Nucleic acid sequences encoding expandable hiv mosaic proteins
WO2011057254A2 (en) 2009-11-09 2011-05-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Simian adenoviral vector-based vaccines
CA2779632C (en) 2009-11-09 2019-08-20 Jason Gall Simian adenovirus and methods of use
WO2012021730A2 (en) 2010-08-11 2012-02-16 Genvec, Inc. Respiratory syncytial virus (rsv) vaccine
WO2012083297A2 (en) 2010-12-17 2012-06-21 Genvec, Inc. Adenoviral vectors with modified hexon regions
US8920813B2 (en) 2010-12-20 2014-12-30 Genvec, Inc. Adenoviral vector-based dengue fever vaccine
EP2747774A4 (en) 2011-09-09 2015-02-11 Biomed Realty L P METHOD AND COMPOSITIONS FOR CONTROLLING VIRUS PROTECTION
WO2013154744A1 (en) * 2012-04-13 2013-10-17 Cornell University Development of a highly efficient second generation nicotine-conjugate vaccine to treat nicotine addiction
US9790519B2 (en) 2012-05-29 2017-10-17 Genvec, Inc. Modified serotype 28 adenoviral vectors
DK2880160T3 (en) * 2012-08-03 2019-01-14 Cedars Sinai Medical Center ISOLATION OF TRANSPORT INCREASING MUTANTS OF PHARMACEUTICAL PROCESSING PROTEIN
CA3115891A1 (en) 2013-03-14 2014-09-25 Salk Institute For Biological Studies Oncolytic adenovirus compositions
TWI710635B (zh) 2014-10-09 2020-11-21 美商珍維克公司 編碼人類無調同源物-1(hath1)之腺病毒載體
WO2017147265A1 (en) 2016-02-23 2017-08-31 Salk Institute For Biological Studies High throughput assay for measuring adenovirus replication kinetics
KR20180112024A (ko) 2016-02-23 2018-10-11 더 솔크 인스티튜트 포 바이올로지칼 스터디즈 바이러스 동역학에 미치는 영향 최소화를 위한 치료용 아데노바이러스의 외인성 유전자 발현
CA3038968A1 (en) 2016-09-30 2018-04-05 Genvec, Inc. Adenovectors for delivery of therapeutic genetic material into t cells
WO2018111767A1 (en) 2016-12-12 2018-06-21 Salk Institute For Biological Studies Tumor-targeting synthetic adenoviruses and uses thereof
WO2021118924A2 (en) 2019-12-12 2021-06-17 Ting Therapeutics Llc Compositions and methods for the prevention and treatment of hearing loss

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9223084D0 (en) * 1992-11-04 1992-12-16 Imp Cancer Res Tech Compounds to target cells
US5543328A (en) * 1993-08-13 1996-08-06 Genetic Therapy, Inc. Adenoviruses having modified fiber proteins
US5559099A (en) * 1994-09-08 1996-09-24 Genvec, Inc. Penton base protein and methods of using same
US5770442A (en) * 1995-02-21 1998-06-23 Cornell Research Foundation, Inc. Chimeric adenoviral fiber protein and methods of using same

Also Published As

Publication number Publication date
EP0863987A2 (en) 1998-09-16
BG102554A (en) 1999-04-30
NZ323834A (en) 2000-01-28
ATE382694T1 (de) 2008-01-15
EE9800160A (et) 1998-12-15
WO1997020051A2 (en) 1997-06-05
JP3420586B2 (ja) 2003-06-23
EP1616961A1 (en) 2006-01-18
IL124654A0 (en) 1998-12-06
MX9804203A (es) 1998-10-31
AU1086897A (en) 1997-06-19
CA2236912C (en) 2006-04-25
EP1518933A1 (en) 2005-03-30
WO1997020051A3 (en) 1997-08-28
AU724189B2 (en) 2000-09-14
EA199800475A1 (ru) 1998-12-24
CZ162398A3 (cs) 1998-10-14
BR9612685A (pt) 1999-07-20
PL327038A1 (en) 1998-11-09
SK72298A3 (en) 1998-12-02
NO982417D0 (no) 1998-05-27
CA2236912A1 (en) 1997-06-05
NO982417L (no) 1998-07-06
EP0863987B1 (en) 2008-01-02
JPH11501219A (ja) 1999-02-02

Similar Documents

Publication Publication Date Title
IS4754A (is) Genaferjur og aðferðir fyrir genaflutning inn í frumur
ATE382695T1 (de) Targeting von adenoviren mit hilfe von konformationsbeschränkten peptidmotiven
ATE213022T1 (de) Adenovirale vektoren für die gentherapie
EP0866721A4 (en) ADENOVIRAL TARGET VECTORS
SG165153A1 (en) Simian adenovirus nucleic acid and amino acid sequences, vectors containing same, and methods of use
NO20004563D0 (no) Modifisert adenovirus som inneholder et fibererstatningsprotein
DE69637545D1 (de) Chimärisches , adenovirales faserprotein und verfahren zu dessen verwendung
DK0707071T3 (da) Rekombinante vektorer afledt fra adenovirus til anvendelse i genterapi
ATE336587T1 (de) Adenoviren-vektor systeme und zelllinien
DE69535103D1 (de) Rekombinanter adenovirus welcher eine chimäre penton-base aufweist
ATE196502T1 (de) Neue komplementations-zelllinien für defekte adenovirale vektoren
WO2001073060A3 (en) 18221, dual specificity phosphatase and uses thereof
ES2170622A1 (es) Clones y vectores infectivos derivados de coronavirus y sus aplicaciones.
EP0804609A4 (en) NEW GENES OF RESPONSE p53
ATE420182T1 (de) Verpackungszellinien in der verwendung zur erleichterung der entwicklung hocheffizienter adenoviraler vektoren
WO2000009693A3 (en) Identification of the gene causing the mouse scurfy phenotype and its human ortholog
AU4903099A (en) Targeted integration into chromosomes using retroviral vectors
NO951315L (no) Ökt produksjon av utsondrede proteiner fra rekombinante eukaryote-celler
NO331102B1 (no) Promotor, ekspresjonsvektor og vert, og fremgangsmate for a produsere et aktuelt protein
CA2237059A1 (en) Targeted adenovirus vectors
WO2004011489A3 (fr) Adenovirus modifies pour changer leur tropisme, de preference pour le ciblage des lymphocytes b ou des cellules ovariennes